Testing microRNA and serum markers in early liver cancer patients treated with thermoablation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will collect samples from adults with hepatocellular carcinoma who are undergoing thermoablation to identify circulating microRNAs and metabolites associated with treatment response. The project will use pretreatment liver biopsy data and patient-derived cell lines for metabolic and molecular analyses, complemented by bioinformatics to understand reprogramming mechanisms. No experimental therapy is being tested; instead, the goal is to find biomarkers that might predict outcomes after locoregional treatment. Findings could inform personalized management and follow-up strategies for this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18
* Diagnosis of hepatocarcinoma confirmed by radiology (LIRADS criteria/triphasic diagnostics) or by biopsy.
* Indication for thermoablation treatment (for radiofrequency) based on the judgment of the hepatologist/surgeon.
* Informed consent signed by the patient.

Exclusion Criteria:

* Presence of metastatic liver lesions of other origins.
* History of liver transplant.
* Severe, uncorrectable coagulopathy, contraindicating liver biopsy (where necessary) or ablative procedure.
* Patient refusal to participate in the study or inability to obtain informed consent.
* Pregnant women.

Where it's running

• IRCCS Policlinico di Sant'Orsola
  Bologna, Emilia-Romagna, Italy Recruiting

Study contacts

• Study coordinator: Andrea Boccatonda, MD
• Email: andrea.boccatonda@aosp.bo.it
• Phone: +39 0512143265

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mapping epigenetic changes that help liver cancer evade the immune system using detailed molecular profiling.

  This project will use tumor and blood samples from people with hepatocellular carcinoma to see if specific noncoding RNAs and epigenetic changes are linked to T cell dysfunction in tumors.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07432347

• Skin tests to check biotherapy allergies in cancer patients

  We are testing skin tests to see if cancer patients treated with biotherapies have allergies or hypersensitivity to those drugs.

  Recruiting University Hospital, Angers · Angers · NCT06971848

• Predicting liver disease complications and cancer development in patients

  This study is testing if a new way of monitoring patients with advanced liver disease can help predict serious health issues and cancer better than standard care.

  Recruiting University Hospital Muenster · Münster, North Rhine-Westphalia · NCT06523608

• Evaluating mutations in solid tumors using liquid biopsy and genome sequencing

  This study is trying to see if a blood test can find important gene changes in patients with advanced solid tumors to help doctors choose the best treatments for them.

  Recruiting Centro di Riferimento Oncologico - Aviano · Aviano, Pordonone · NCT06028724

• Infusion of checkpoint inhibitors and chemotherapy for advanced solid tumors

  This study is testing if giving a mix of immune therapy and chemotherapy directly to tumors helps people with advanced cancers feel better compared to the usual way of giving these treatments.

  Recruiting Phase 2/3 Second Affiliated Hospital of Guangzhou Medical University · Guanzhou, Guangdong · NCT03755739

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.